Biogen ALS Drug Showed No Benefit, O'Neill Says

Jan. 3 (Bloomberg) -- Gilmore O’Neill, vice president of clinical development at Biogen Idec Inc., talks with Bloomberg's Meg Tirrell about the company's announcement that its experimental drug for amyotrophic lateral sclerosis failed to help patients in a clinical trial. Biogen sank 1.4 percent to $147.86 at 4 p.m. New York time after saying it will end development of the medicine for ALS, also known as Lou Gehrig’s disease. (Source: Bloomberg)
Does Apple TV Need a Revamp?
16:15 - Homebrew VC Partner Hunter Walk, Technalysis Founder Bob O’Donnell and IDC Chief Research Officer Crawford Del Prete discuss Apple to unveil a new TV box this fall and the future of Apple’s streaming service. They speak with Bloomberg’s Emily Chang on “Bloomberg West.” (Source: Bloomberg)
  • Why Would Microsoft Invest in Uber?
  • Why U.S. Wage Growth Has Screeched to a Halt
  • The China Slowdown Felt Around the World